UY39555A - Terapia de células car-t dirigida a bcma para mieloma múltiple - Google Patents
Terapia de células car-t dirigida a bcma para mieloma múltipleInfo
- Publication number
- UY39555A UY39555A UY0001039555A UY39555A UY39555A UY 39555 A UY39555 A UY 39555A UY 0001039555 A UY0001039555 A UY 0001039555A UY 39555 A UY39555 A UY 39555A UY 39555 A UY39555 A UY 39555A
- Authority
- UY
- Uruguay
- Prior art keywords
- car
- subject
- multiple myeloma
- bcma
- cell therapy
- Prior art date
Links
- 208000034578 Multiple myelomas Diseases 0.000 title abstract 2
- 206010035226 Plasma cell myeloma Diseases 0.000 title abstract 2
- 238000011357 CAR T-cell therapy Methods 0.000 title 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000007660 Residual Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/21—Transmembrane domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/22—Intracellular domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Hematology (AREA)
- Mobile Radio Communication Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/133598 WO2022116086A1 (en) | 2020-12-03 | 2020-12-03 | Bcma-targeted car-t cell therapy for multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39555A true UY39555A (es) | 2022-06-30 |
Family
ID=79270135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039555A UY39555A (es) | 2020-12-03 | 2021-12-03 | Terapia de células car-t dirigida a bcma para mieloma múltiple |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20220265710A1 (https=) |
| EP (1) | EP4255450A1 (https=) |
| JP (1) | JP2023551877A (https=) |
| KR (1) | KR20230118556A (https=) |
| CN (1) | CN116888147A (https=) |
| AR (1) | AR124248A1 (https=) |
| AU (1) | AU2021392708A1 (https=) |
| CA (1) | CA3203603A1 (https=) |
| IL (1) | IL303312A (https=) |
| JO (1) | JOP20230122A1 (https=) |
| MA (1) | MA71426A (https=) |
| MX (1) | MX2023006371A (https=) |
| TW (1) | TW202237637A (https=) |
| UY (1) | UY39555A (https=) |
| WO (2) | WO2022116086A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020378263A1 (en) | 2019-11-05 | 2022-06-23 | Janssen Biotech, Inc. | BCMA-targeted CAR-T cell therapy of multiple myeloma |
| CN116096498A (zh) * | 2020-05-04 | 2023-05-09 | 生物诊断有限公司 | 诊断设备 |
| WO2024146398A1 (zh) * | 2023-01-04 | 2024-07-11 | 北京艺妙神州医药科技有限公司 | 分离的抗体、包含该抗体的car及其用途 |
| WO2024206329A1 (en) | 2023-03-27 | 2024-10-03 | Modernatx, Inc. | Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof |
| CA3205511A1 (en) * | 2023-04-19 | 2025-03-17 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| CA2096222C (en) | 1990-11-13 | 1998-12-29 | Stephen D. Lupton | Bifunctional selectable fusion genes |
| WO1994028143A1 (en) | 1993-05-21 | 1994-12-08 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5885827A (en) | 1996-01-23 | 1999-03-23 | The Regents Of The Universtiy Of California | Eukaryotic high rate mutagenesis system |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| BRPI0807952A2 (pt) | 2007-02-20 | 2014-06-10 | Anaptysbio Inc | Sistemas de hipermutação somática |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| CN105777911B (zh) * | 2016-04-12 | 2019-07-02 | 上海优卡迪生物医药科技有限公司 | 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用 |
| SG10202012157QA (en) * | 2016-06-07 | 2021-01-28 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
| EP4282877A3 (en) * | 2016-08-10 | 2024-02-21 | Legend Biotech Ireland Limited | Chimeric antigen receptors targeting bcma and methods of use thereof |
| CN108276493B (zh) * | 2016-12-30 | 2023-11-14 | 南京传奇生物科技有限公司 | 一种嵌合抗原受体及其应用 |
| CN108395478A (zh) * | 2017-02-04 | 2018-08-14 | 上海恒润达生生物科技有限公司 | 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途 |
| CN119529091A (zh) * | 2018-06-19 | 2025-02-28 | 南京传奇生物科技有限公司 | 工程化的细胞及其用途 |
| JP2021532742A (ja) * | 2018-07-26 | 2021-12-02 | ナンジン レジェンド バイオテック カンパニー, リミテッドNanjing Legend Biotech Co., Ltd. | Ｎｅｆを含むｔ細胞及びその生成方法 |
-
2020
- 2020-12-03 WO PCT/CN2020/133598 patent/WO2022116086A1/en not_active Ceased
-
2021
- 2021-12-02 TW TW110145018A patent/TW202237637A/zh unknown
- 2021-12-02 US US17/540,736 patent/US20220265710A1/en active Pending
- 2021-12-03 CN CN202180080095.0A patent/CN116888147A/zh active Pending
- 2021-12-03 UY UY0001039555A patent/UY39555A/es unknown
- 2021-12-03 MX MX2023006371A patent/MX2023006371A/es unknown
- 2021-12-03 WO PCT/CN2021/135295 patent/WO2022117068A1/en not_active Ceased
- 2021-12-03 IL IL303312A patent/IL303312A/en unknown
- 2021-12-03 US US18/039,420 patent/US20240000836A1/en active Pending
- 2021-12-03 EP EP21838974.0A patent/EP4255450A1/en active Pending
- 2021-12-03 AR ARP210103371A patent/AR124248A1/es unknown
- 2021-12-03 JP JP2023533310A patent/JP2023551877A/ja active Pending
- 2021-12-03 KR KR1020237018245A patent/KR20230118556A/ko active Pending
- 2021-12-03 CA CA3203603A patent/CA3203603A1/en active Pending
- 2021-12-03 MA MA71426A patent/MA71426A/fr unknown
- 2021-12-03 AU AU2021392708A patent/AU2021392708A1/en active Pending
-
2023
- 2023-05-30 JO JOJO/P/2023/0122A patent/JOP20230122A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA71426A (fr) | 2025-04-30 |
| WO2022117068A1 (en) | 2022-06-09 |
| MX2023006371A (es) | 2023-07-31 |
| US20220265710A1 (en) | 2022-08-25 |
| CN116888147A (zh) | 2023-10-13 |
| JP2023551877A (ja) | 2023-12-13 |
| KR20230118556A (ko) | 2023-08-11 |
| WO2022116086A1 (en) | 2022-06-09 |
| CA3203603A1 (en) | 2022-06-09 |
| EP4255450A1 (en) | 2023-10-11 |
| TW202237637A (zh) | 2022-10-01 |
| AU2021392708A1 (en) | 2023-06-22 |
| IL303312A (en) | 2023-07-01 |
| AR124248A1 (es) | 2023-03-01 |
| US20240000836A1 (en) | 2024-01-04 |
| JOP20230122A1 (ar) | 2023-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39555A (es) | Terapia de células car-t dirigida a bcma para mieloma múltiple | |
| MX2024005461A (es) | Terapia de celulas car-t dirigida a bcma para mieloma multiple. | |
| MX2021005024A (es) | Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b. | |
| CR11724A (es) | Agente para tratar enfermedades | |
| MX2016005666A (es) | Anticuerpos anti-cd38 especificos para tratar canceres humanos. | |
| AR087356A1 (es) | Terapia de combinacion para el tratamiento de sintomas de tumores malignos de celulas b cd19que comprende inmunoconjugado maitansinoide anti-cd19 y rituximab | |
| MX2022001623A (es) | Metodos para tratar la enfermedad de fabry en pacientes que tienen una mutacion en el gen gla. | |
| MX2024005237A (es) | Compuesto que tiene actividad de degradacion de la proteina btk, y usos medicos del mismo. | |
| EP4151210A3 (en) | Pyridine-carboline derivatives as mchr1 antagonists for use in therapy | |
| AR122341A1 (es) | Método para el tratamiento de cáncer utilizando célula adyuvante artificial (aavc) | |
| MX2022009041A (es) | Metodos de dosificacion y tratamiento de linfoma folicular y linfoma de zona marginal en terapia celular adoptiva. | |
| ECSP23076276A (es) | Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1 | |
| MX2022001153A (es) | Regimen de dosificacion y administracion para el tratamiento o prevencion de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab. | |
| RU2676836C2 (ru) | Устройство для лечения недостаточности иммунных функций и регулирования метаболизма | |
| Barlogie | Management of multiple myeloma | |
| Hansen | UAB-led study shows drug effectiveness in reducing glucocorticoid-induced bone loss | |
| AR124317A1 (es) | Tratamiento de pacientes con cáncer con terapias con linfocitos infiltrantes de tumor en combinación con inhibidores de braf y/o inhibidores de mek | |
| AR131998A1 (es) | Terapia celular para el tratamiento de enfermedades autoinmunes sistémicas | |
| RU2391100C1 (ru) | Способ лечения больных грибковыми заболеваниями ногтей | |
| Park et al. | The effect of rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP) chemotherapy in patients with ocular adnexal extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma | |
| CO2025001817A2 (es) | Método para tratar una enfermedad mediada por linfocitos t | |
| Kohli et al. | Low Level Laser Therapy in Acupuncture Mode for Management of Pain due to DeQuervain’s Disease | |
| Gross et al. | Radiotherapy compared to extracorporeal shockwave therapy for supraspinatus tendinitis-randomised prospective single-blind trial with two-sample parallel group design | |
| 丁瑋甄 et al. | CyberKnife Radiosurgery for Refractory Trigeminal Neuralgia: A Single Institutional Experience | |
| Raza | Advances in HIV/AIDS Treatment: From Antiretrovirals to Cure Research |